N/A
Manufactured by Teva Neuroscience, Inc.
23,100 FDA adverse event reports analyzed
Last updated: 2026-04-14
RASAGILINE MESYLATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Teva Neuroscience, Inc.. The most commonly reported adverse reactions for RASAGILINE MESYLATE include FALL, HALLUCINATION, DYSKINESIA, DRUG INEFFECTIVE, TREMOR. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RASAGILINE MESYLATE.
Out of 10,680 classified reports for RASAGILINE MESYLATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 23,100 FDA FAERS reports that mention RASAGILINE MESYLATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FALL, HALLUCINATION, DYSKINESIA, DRUG INEFFECTIVE, TREMOR, DIZZINESS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Teva Neuroscience, Inc. in connection with RASAGILINE MESYLATE. Always verify the specific product and NDC with your pharmacist.